profit from every $100 of sales.
$0$100
Edwards Lifesciences
$107.15+1.28% today
+24.4% in 1 year
1-year low $75.871-year high $107.15
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $57.39 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Edwards Lifesciences sold, what it kept, and what it did with the cash.
Sales went from $4.46 billion in 2022 to $6.07 billion in 2025, with $1.07 billion of profit last year.
SalesProfit
Edwards Lifesciences handed back 67% of the cash it generated last year.
Buybacks $893M
Free cash flow 2025$1.3B
Bought back its own shares$893M
Paid as dividends–
Cash vs. debt$2.9B vs. $705M
Edwards Lifesciences vs. similar companies
Edwards Lifesciences grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Edwards Lifesciences | 57.4× · Expensive | ||
 Abbott Laboratories | 28.8× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 36.3× · Expensive | ||
 Siemens Healthineers | 25.3× · Fair price |
Compare Edwards Lifesciences with Intuitive Surgical · Steris
AI analysis
An AI analyst reads Edwards Lifesciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 4,386 | 5,233 | 4,464 | 5,010 | 5,440 | 6,068 | |
| 3,306 | 3,984 | 3,740 | 4,032 | 4,322 | 4,733 | |
| – | – | 1,539 | 1,486 | 1,480 | 1,636 | |
| 1,040 | 1,855 | 1,678 | 1,535 | 1,723 | 1,450 | |
| 823 | 1,503 | 1,522 | 1,402 | 4,175 | 1,074 | |
| 1.30 | 2.38 | 2.44 | 2.30 | 6.97 | 1.83 | |
| 75.4% | 76.1% | 83.8% | 80.5% | 79.5% | 78.0% | |
| – | – | 34.5% | 29.7% | 27.2% | 27.0% | |
| 18.8% | 28.7% | 34.1% | 28.0% | 76.7% | 17.7% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 7,237 | 8,503 | 8,293 | 9,363 | 13,055 | 13,697 |
| Cash | 1,183 | 863 | 769 | 1,132 | 3,045 | 2,938 |
| Total debt | 695 | 690 | 691 | 685 | 700 | 705 |
| Total liabilities | 2,663 | 2,667 | 2,486 | 2,644 | 2,992 | 3,360 |
| 4,574 | 5,836 | 5,807 | 6,650 | 9,998 | 10,338 | |
| 632 | 631 | 624 | 609 | 599 | 586 | |
| 14.0% | 20.8% | 18.7% | 15.0% | 11.6% | 9.3% | |
| 18.0% | 25.8% | 26.2% | 21.1% | 41.8% | 10.4% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1,054 | 1,732 | 1,218 | 896 | 542 | 1,595 | |
| 407 | 326 | 265 | 266 | 282 | 260 | |
| 647 | 1,406 | 953 | 630 | 260 | 1,335 | |
| Dividends paid | – | – | – | – | – | – |
| 625 | 513 | 1,727 | 880 | 1,159 | 893 | |
| 93 | 109 | 127 | 139 | 162 | 158 |
Valuation
- 57.4×
- 35.6×
- 8.11
- 5.5×
- 10.2×
- 46.2×
- 41.0×
- 2.2%
- 1.7%
- 0.0%
Profitability
- 78.0%
- 27.0%
- 17.7%
- 22.8%
- 9.5%
- 14.0%
- 10.6%
- 8.2%
- 14.6%
- 17.3%
Growth
- +6.7%
- +7.1%
- +360.5%
- –
- −2.1%
Financial health
- -1.5×
- 0.07
- 5.3%
- 63.4×
- 3.72
- 3.63
- 0.47
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 31%of 946
Top 14%of 871
Bottom 19%of 563
Bottom 34%of 867
Top 41%of 986
What analysts expect
- Average price target
- $97.08
- Range
- $85.00 – $110.00
- 9 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 23, 2026 | 0.78 | 0.73 | +7.0% |
| Feb 10, 2026 | 0.58 | 0.62 | −6.1% |
| Oct 30, 2025 | 0.67 | 0.60 | +12.4% |
| Jul 24, 2025 | 0.67 | 0.62 | +7.4% |
| Apr 23, 2025 | 0.64 | 0.60 | +7.4% |
| Feb 11, 2025 | 0.59 | 0.55 | +7.1% |
| Oct 24, 2024 | 0.67 | 0.67 | +0.8% |
| Jul 24, 2024 | 0.70 | 0.69 | +1.4% |
News
Is There Any Reason To Invest In Edwards Lifesciences Stock?Yahoo Finance · Nov 14, 2026AI boom echoes 1997 Asian financial crisis: SocGen's Albert EdwardsSeeking Alpha · Oct 11, 2026Edwards Lifesciences praises CMS NCD on transcatheter aortic valve replacementSeeking Alpha · Sep 10, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
60Pass
Benjamin Graham
45No pass
Philip Fisher
59No pass
Peter Lynch
30No pass
Joel Greenblatt
6No pass
Charlie Munger
66Pass
Terry Smith
61Pass
Questions about Edwards Lifesciences
Is Edwards Lifesciences a good stock to buy?
A solid business, but the price is high. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Edwards Lifesciences AI analysis
What does Edwards Lifesciences do?
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It is in Medical Devices, based in Irvine, CA, United States, with 16,000 employees.
Does Edwards Lifesciences pay a dividend?
No. Edwards Lifesciences does not pay a dividend at the moment; in 2025 it returned $893 million to shareholders by buying back its own shares.
Is Edwards Lifesciences stock halal?
Yes. Edwards Lifesciences passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Edwards Lifesciences stock done over the past year?
Up 24.4% over the past twelve months, to $107.15. It traded between $75.87 and $107.15, close to its high.
Who are Edwards Lifesciences's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Siemens Healthineers. The peers table on this page compares their profit, growth and price with Edwards Lifesciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.